Company news
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) news
Every Fulcrum Therapeutics, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases — page 3
Fulcrum Therapeutics® to Host Fourth Quarter and Full Year 2021 Financial Results Conference Call and Webcast on Thursday, March 3, 2022 at 8:00 a.m. ET
February 24, 2022
Fulcrum Therapeutics® to Participate in 11th Annual SVB Leerink Global Healthcare Conference
February 10, 2022
Fulcrum Therapeutics® Announces Upcoming Milestones to Support Its Mission of Treating the Root Cause of Rare Genetic Diseases
January 10, 2022
Fulcrum Therapeutics® to Present at the 40th Annual J.P. Morgan Healthcare Conference
January 6, 2022
Fulcrum Therapeutics® Appoints Esther Rajavelu as Chief Financial Officer
January 4, 2022
Fulcrum Therapeutics® Announces Additional HBG mRNA Induction from Higher Dose Cohorts in Phase 1 Healthy Adult Volunteer Trial of FTX-6058 for Sickle Cell Disease and New Preclinical Mechanism Data
December 6, 2021
Fulcrum Therapeutics® Appoints Sonja L. Banks to its Board of Directors
November 17, 2021
Fulcrum Therapeutics® Reports Recent Business Highlights and Third Quarter 2021 Financial Results
November 4, 2021
Fulcrum Therapeutics™ to Participate in Upcoming November Investor Conferences
November 3, 2021
Fulcrum Therapeutics™ to Host Third Quarter 2021 Financial Results Conference Call and Webcast on Thursday, November 4, 2021 at 8:00 a.m. ET
October 28, 2021
Fulcrum Therapeutics™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
October 1, 2021
Fulcrum Therapeutics™ Announces Multiple Presentations During the Virtual Congress of the World Muscle Society
September 20, 2021
Fulcrum Therapeutics™ Appoints Mel Hayes as Chief Commercial Officer
September 8, 2021
Fulcrum Therapeutics™ to Participate in Upcoming Investor Conferences
September 2, 2021
Fulcrum Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
August 16, 2021
Fulcrum Therapeutics Announces Pricing of $125 Million Public Offering of Common Stock
August 11, 2021
Fulcrum Therapeutics Reports Recent Business Highlights and Second Quarter 2021 Financial Results
August 10, 2021
Fulcrum Therapeutics Announces Positive Interim Results from Phase 1 Healthy Adult Volunteer Trial of FTX-6058 for Sickle Cell Disease
August 10, 2021
Fulcrum Therapeutics to Host Second Quarter 2021 Financial Results Conference Call and Webcast on Tuesday, August 10, 2021 at 8:00 a.m. ET
August 4, 2021
Fulcrum Therapeutics Announces Results from ReDUX4 Trial with Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD) Demonstrating Slowed Disease Progression and Improved Function
June 24, 2021
Fulcrum Therapeutics Announces Multiple Presentations at the 28th Annual FSHD Society International Research Congress (IRC)
June 21, 2021
Fulcrum Therapeutics Announces U.S. Food and Drug Administration Grants Fast Track Designation to Losmapimod for the Potential Treatment of Facioscapulohumeral Muscular Dystrophy (FSHD)
May 12, 2021
Fulcrum Therapeutics to Present at the BofA Securities 2021 Virtual Health Care Conference
May 7, 2021
Fulcrum Therapeutics Reports Recent Business Highlights and First Quarter 2021 Financial Results
May 6, 2021
Fulcrum Therapeutics Appoints Christopher Morabito, M.D. as Chief Medical Officer
May 6, 2021
Fulcrum Therapeutics to Host First Quarter 2021 Financial Results Conference Call and Webcast on Thursday, May 6, 2021 at 8:00 a.m. ET
April 29, 2021
Fulcrum Therapeutics Presents Published Structure of Investigational Small Molecule FTX-6058 at the American Chemical Society (ACS) Spring 2021 Virtual Conference
April 9, 2021
Fulcrum Therapeutics Appoints Judith A. Dunn, Ph.D. as President of Research and Development
March 24, 2021
Fulcrum Therapeutics Presents Data for Potential FSHD Biomarker and Clinical Outcome Assessments at 2021 Muscular Dystrophy Association (MDA) Virtual Clinical & Scientific Conference
March 18, 2021
Fulcrum Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2020 Financial Results
March 4, 2021
Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call and Webcast on Thursday, March 4, 2021 at 8:00 a.m. ET
February 26, 2021
Fulcrum Therapeutics Recognizes Rare Disease Day 2021
February 26, 2021
Fulcrum Therapeutics to Participate in Upcoming Investor Conferences
February 19, 2021
Fulcrum Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
January 22, 2021
Fulcrum Therapeutics Announces Promotion of Christopher Moxham, Ph.D., to Chief Scientific Officer
January 19, 2021
Fulcrum Therapeutics to Participate in the H.C. Wainwright BioConnect 2021 Conference
January 6, 2021
Fulcrum Therapeutics to Host Virtual Key Opinion Leader Event Featuring FTX-6058 for Sickle Cell Disease
December 9, 2020
Fulcrum Therapeutics Presents Updated Data on Sickle Cell Disease Program at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition
December 5, 2020
Fulcrum Therapeutics Reports Recent Business Highlights and Third Quarter 2020 Financial Results
November 10, 2020
Fulcrum Therapeutics Announces Multiple Presentations During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition
November 4, 2020
Fulcrum Therapeutics to Host Third Quarter 2020 Financial Results Conference Call and Webcast on Tuesday, November 10, 2020 at 8:00 a.m. ET
November 3, 2020
Fulcrum Therapeutics to Initiate Phase 1 Trial with FTX-6058 for Sickle Cell Disease
October 5, 2020
Fulcrum Therapeutics Announces Multiple Presentations During the Virtual 25th International Congress of the World Muscle Society
October 1, 2020
Fulcrum Therapeutics Announces Preclinical Proof-of-Concept Data for FTX-6058 at the Virtual 14th Annual Sickle Cell Disease Research & Educational Symposium and 43rd National Sickle Cell Disease Scientific Meeting
September 25, 2020
Fulcrum Therapeutics Reports Recent Business Highlights and Second Quarter 2020 Financial Results
August 11, 2020
Fulcrum Therapeutics Announces Interim Analysis Data from its ReDUX4 Trial in Facioscapulohumeral Muscular Dystrophy (FSHD)
August 11, 2020
Fulcrum Therapeutics to Host Second Quarter 2020 Financial Results Conference Call and Webcast on Tuesday, August 11, 2020 at 8:00 a.m. ET
August 5, 2020
MyoKardia and Fulcrum Therapeutics Announce Multi-Target Collaboration to Discover Novel Targeted Therapies for Genetic Cardiomyopathies
July 21, 2020
Fulcrum Therapeutics Announces Initiation of Multi-Center Phase 3 (LOSVID) Trial with Losmapimod for Hospitalized COVID-19 Patients
June 24, 2020
Fulcrum Therapeutics to Evaluate Losmapimod as Potential Treatment for COVID-19
June 10, 2020